Each trust to do 5-year review on anaplastic thyroid cancers., detailing length of symptoms, management, survival and palliation Action: TM to draft proforma. TM 5.3 U3s from radiologists - this is perhaps too heterogenous group of patients. What is in this classification? TM suggested one audit on the interface between cytology and relation to final histology. Presentation by TM FNA outcomes”. TM “Thy3 6. Research /Clinical Trials 6.1 Not many Thyroid cancer trials available at the moment. Most are in the USA. Currently included with Head & Neck data. WC will send details to LB. WC requested nomination for subspecialty lead for thyroid. Suggested that Andy Goodman may agree to take on this role. ION trial still ongoing in Exeter. WC Action: WC to contact AG 6.2 Dr Katy Newbold at the Marsden is undertaking a phase 2 trial for new TKIs in Medullary cancer relapse. Action: WC to send research info to TM so he can discuss at next meeting. WC 7. Election of Chair 7.1 TM confirmed he is the interim Chair but is happy to carry on as Chair if that is what the group would like. AR nominated TM as Chair and this was agreed by TM and accepted by the Group. TM agreed to Chair this group for two meetings per year for the next three years. 8. Any Other Business 8.1 agreed that CB act as Patients Representative Lead Patient Representation – and CNSs from each trust would represent the patients’ views. The representatives would not necessarily have to be present at the NSSG meetings, but their views relayed to the team. 9. Date of Next Meetings Friday 13th May 2016 in the Burrator Room, Lakeside Conference Centre, Roadford Lake, Devon PL16 0RL 10:30-12:30pm Friday 18th October 2016 in the Burrator Room, Lakeside Conference Centre, Roadford Lake, Devon PL16 0RL 10:30-12:30pm
5.3 Each trust to do 5-year review on anaplastic thyroid cancers., detailing length of symptoms, management, survival and palliation Action: TM to draft proforma. U3s from radiologists - this is perhaps too heterogenous group of patients. What is in this classification? TM suggested one audit on the interface between cytology and relation to final histology. Presentation by TM “Thy3 FNA outcomes”. TM TM 6. 6.1 6.2 Research /Clinical Trials Not many Thyroid cancer trials available at the moment. Most are in the USA. Currently included with Head & Neck data. WC will send details to LB. WC requested nomination for subspecialty lead for thyroid. Suggested that Andy Goodman may agree to take on this role. ION trial still ongoing in Exeter. Action: WC to contact AG Dr Katy Newbold at the Marsden is undertaking a phase 2 trial for new TKIs in Medullary cancer relapse. Action: WC to send research info to TM so he can discuss at next meeting. WC WC 7. 7.1 Election of Chair TM confirmed he is the interim Chair but is happy to carry on as Chair if that is what the group would like. AR nominated TM as Chair and this was agreed by TM and accepted by the Group. TM agreed to Chair this group for two meetings per year for the next three years. 8. 8.1 Any Other Business Patient Representation – agreed that CB act as Patients Representative Lead and CNSs from each trust would represent the patients’ views. The representatives would not necessarily have to be present at the NSSG meetings, but their views relayed to the team. 9. Date of Next Meetings Friday 13th May 2016 in the Burrator Room, Lakeside Conference Centre, Roadford Lake, Devon PL16 0RL 10:30-12:30pm Friday 18th October 2016 in the Burrator Room, Lakeside Conference Centre, Roadford Lake, Devon PL16 0RL 10:30-12:30pm